SWEDEGENE is a Swedish nation-wide sample collection established to facilitate studies of clinical and genetic risk factors for adverse drug reactions (ADRs). Most cases are recruited among patients reported to the ADR registry at the Swedish Medical Products Agency by health-care professionals. Clinical data are collected both from medical and laboratory records and through interviews using standardized questionnaires. Genome-wide scans and whole-genome sequencing are done, and association studies are conducted using mainly controls from the Swedish TwinGene biobank with data on diagnoses and prescribed drugs. SWEDEGENE was established in 2008 and currently contains DNA and information from about 2550 adults who have experienced specific ADRs, and from 580 drug exposed controls. Results from genome-wide association studies have now been published, and data from whole-genome sequencing are being analyzed. SWEDEGENE has the potential to offer a new means of developing individualized and safe drug therapy through patient pre-treatment screening.

中文翻译：

---

SWEDEGENE-瑞典全国范围内的DNA样本收藏品，用于药物不良反应严重的药物基因组学研究。

SWEDEGENE是瑞典全国范围内的样本集合，旨在促进药物不良反应（ADR）的临床和遗传危险因素研究。大多数病例是由医疗保健专业人员在瑞典医疗产品局向ADR注册中心报告的患者中招募的。从医学和实验室记录以及通过使用标准问卷的访谈中收集临床数据。完成了全基因组扫描和全基因组测序，并主要使用瑞典TwinGene生物库中的对照以及诊断和处方药数据进行了关联研究。SWEDEGENE成立于2008年，目前包含约2550名经历过特定ADR的成年人以及580名接触药物的对照组的DNA和信息。全基因组关联研究的结果现已发布，正在分析全基因组测序的数据。SWEDEGENE有潜力提供通过患者预处理筛选开发个性化，安全药物治疗的新方法。